Conference
ANNEXA (TM)-A PART 2: A phase 3 randomized, double-blind, placebo-controlled trial demonstrating sustained reversal of apixaban-induced anticoagulation in older subjects by andexanet ALFA (PRT064445), a universal antidote for factor XA (FXA) inhibitors
Authors
Crowther M; Gold A; Lu G; Leeds JM; Wiens BL; Mathur V; Castillo J; Conley PB; Connolly S; Curnutte JT
Volume
13
Pagination
pp. 84-85
Publisher
WILEY-BLACKWELL
Publication Date
June 1, 2015
Conference proceedings
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
ISSN
1538-7933